B. Douglas Smith

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

B. Douglas Smith, Mark J. Levis, Miloslav Beran et al. · Blood · 2004 · 622 citations

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann et al. · Leukemia · 2018 · 474 citations · Full text

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 469 citations

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Leo Luznik, Javier Bolaños‐Meade, Marianna Zahurak et al. · Blood · 2010 · 396 citations · Full text

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Mark J. Levis, Farhad Ravandi, Eunice S. Wang et al. · Blood · 2011 · 395 citations · Full text